IMW 2021 | Positioning MRD in the myeloma treatment landscape
Niels van de Donk
• 10 Sep 2021
Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, shares his views on the role of measurable residual disease (MRD) in the treatment for hematologic malignancies such as multiple myeloma. Prof. van de Donk talks on the prognostic value of MRD but also explains the need for more studies that investigate MRD use in determining treatment duration. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Niels van de Donk, MD, PhD, has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis and BMS; and serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Novartis, Bayer, and Servier.
